RT Alex Svanevik 🐧 (@ASvanevik)Go public.On the internet. https://t.co/DBPCc2yVHP ...

Core Viewpoint - X4 Pharmaceuticals has announced a public offering of 45,860,000 shares of common stock priced at $2.90 per share, aiming to raise approximately $135 million to fund the development of its drug mavorixafor and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for up to 700,000 shares at a price of $2.899 each, with an exercise price of $0.001 per share [1]. - The offering is expected to close on October 27, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 6,984,000 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, along with general administrative expenses, capital expenditures, and working capital [2]. Group 3: Company Background - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being an orally available CXCR4 antagonist currently marketed in the U.S. as XOLREMDI® [5]. - The company is conducting a global Phase 3 clinical trial (4WARD) for mavorixafor in patients with chronic neutropenic disorders [5].

Core Points - RAPT Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of the total shares offered [1] - The offering is subject to market conditions and there is no assurance regarding its completion or the actual size and terms [1] - The offering is made under a shelf registration statement filed with the SEC, which was declared effective on August 17, 2023 [3] Company Overview - RAPT is a clinical-stage immunology-based biopharmaceutical company focused on developing novel therapies for inflammatory and immunological diseases [5] - The company utilizes proprietary expertise in immunology to create therapies aimed at modulating critical immune responses [5] Offering Details - Joint bookrunning managers for the offering include Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital [2] - Lead managers for the offering are H.C. Wainwright & Co. and Clear Street [2] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on their website [3]

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a public offering of 3,025,480 shares of common stock priced at $157.00 per share, along with pre-funded warrants for an additional 318,470 shares, aiming to raise approximately $525 million in gross proceeds before expenses [1] Group 1: Offering Details - The offering includes 3,025,480 shares of common stock priced at $157.00 each and pre-funded warrants to purchase up to 318,470 shares at a price of $156.9999 per warrant [1] - The gross proceeds from the offering are expected to be around $525 million, excluding underwriting discounts and commissions [1] - Praxis has granted underwriters a 30-day option to purchase up to 501,592 additional shares at the public offering price [1] Group 2: Underwriters - TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering [2] - Oppenheimer & Co. and H.C. Wainwright & Co. are serving as lead managers for the offering [2] Group 3: Regulatory Information - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing with the SEC on December 23, 2024 [3] - A preliminary prospectus supplement was filed with the SEC on October 16, 2025, with the final prospectus supplement to be filed subsequently [3]

Core Viewpoint - Praxis Precision Medicines, Inc. has announced a proposed public offering of its common stock and prefunded warrants to certain investors, with all securities offered by the company [1] Group 1: Offering Details - The offering will include a 30-day option for underwriters to purchase additional shares up to 15% of the total shares sold at the public offering price, minus underwriting discounts and commissions [1] - The offering is being managed by TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities as joint book-running managers [2] - The offering is made under a shelf registration statement on Form S-3ASR, which became effective upon filing on December 23, 2024 [3] Group 2: Prospectus Information - The proposed offering will be conducted only through a preliminary prospectus supplement and the accompanying base prospectus [3] - Interested parties can obtain a copy of the preliminary prospectus from the specified financial institutions [3]

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR) ("Hyperfine†or the "Company†) today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securities sold in ...

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has announced a public offering of 11 million shares at $12.00 per share, aiming to raise approximately $150 million to support its clinical development and corporate initiatives [1][2]. Group 1: Offering Details - The offering includes 11,000,000 shares of common stock priced at $12.00 each and pre-funded warrants for 1,500,000 shares at $11.999 each, with total gross proceeds expected to be around $150 million before expenses [1]. - The closing of the offering is anticipated on or about October 16, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,875,000 shares at the public offering price [1]. Group 2: Use of Proceeds - Net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [2]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU™, currently in Phase 3 trials for wet AMD and expected to initiate trials for DME in early 2026 [6][8]. - The company has a history of developing four approved drugs over three decades, treating tens of thousands of patients [7].

Core Viewpoint - EyePoint Pharmaceuticals, Inc. has initiated a public offering of $150 million in common stock to support its clinical development and corporate initiatives [1][3]. Group 1: Offering Details - The public offering consists of $150 million in shares, with an option for underwriters to purchase an additional $22.5 million within 30 days [1][2]. - J.P. Morgan, Jefferies, Citigroup, and Guggenheim Securities are the joint book running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the clinical development of DURAVYU™ for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), as well as to support earlier stage pipeline initiatives and general corporate purposes [3]. Group 3: Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, with its lead product candidate being DURAVYU™, which is currently in Phase 3 trials [7]. - DURAVYU™ combines vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E™ technology [7]. - The company has a history of developing four approved drugs over three decades, treating tens of thousands of patients [8].

Core Viewpoint - Hycroft Mining Holding Corporation has announced the exercise of the underwriters' over-allotment option in connection with its public offering of Class A Common Stock, increasing the total shares offered and expected proceeds significantly [1][2]. Offering Details - The underwriters exercised an over-allotment option to purchase an additional 3,295,076 shares at a public offering price of $6.50 per share [1]. - The initial public offering was for 23,076,924 shares, which has now been upsized to a total of 26,372,000 shares, resulting in gross proceeds of approximately $171.4 million, up from an initial estimate of $150 million [2]. - The offering is expected to close on October 14, 2025, subject to customary closing conditions [2]. Use of Proceeds - The net proceeds from the offering will be utilized to expand and accelerate exploration and drilling programs, as well as for general corporate and working capital needs, including the anticipated repayment or repurchase of existing debt obligations [4]. Company Background - Hycroft Mining Holding Corporation is a US-based gold and silver company focused on developing the Hycroft Mine, one of the largest precious metals deposits globally, located in northern Nevada [7]. - The company aims to transition the Hycroft Mine into the next phase of commercial operations for processing sulfide ore and is engaged in a robust exploration drill program to expand high-grade silver systems [7].

Core Viewpoint - Univest Securities announced the closing of a public offering for EPWK Holdings Ltd, raising approximately $8 million to support the company's growth and operations [1][3]. Group 1: Offering Details - The offering consisted of 24,242,425 units, each unit comprising one Class A ordinary share or a pre-funded warrant, along with one warrant to purchase one Class A ordinary share [2]. - The public offering price was set at $0.33 per unit, with warrants having an exercise price of $0.3465 per Class A ordinary share, exercisable for six months from the issuance date [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for research development, business expansion, general working capital, and other corporate purposes [3]. Group 3: Company Background - EPWK Holdings Ltd connects businesses with talent through an innovative crowdsourcing platform, primarily serving small and medium-sized enterprises [7]. - The company was founded by Guohua Huang and operates through subsidiaries and contractual arrangements in China [7]. Group 4: Univest Securities Overview - Univest Securities, established in 1994, provides a range of financial services including investment banking and has raised over $1.5 billion in capital for various issuers since 2019 [6].